MENU
JUN 3, 2020

Immuno-Oncology 2020

LabRoots is pleased to announce the inauguration of the Immuno-Oncology Virtual Event taking place on June 3, 2020. Immuno-oncology is considered by some to be one of the most promising areas of research in the world of anti-cancer therapeutics. Learn from our experts how immunotherapies can work alone, together, or in combination with other treatments to fight cancer.

This years event will include the following tracks and topics:

Latest Trends in Immuno-Oncology

Immunotherapeutic Modalities

  • Current Opportunities and Challenges
  • Emerging Targets for Novel Immuno-Oncology Therapy

Development and Clinical Applications of Cancer Immunotherapies

Recent breakthroughs in immuno-oncology research translate into a paradigm shift with regards to attacking advancing cancer. The benefits of immuno-oncology have resulted in long-lasting tumor regression where surgery, radiotherapy, chemotherapy, and targeted therapy proved less effective.

Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open 6 months from the date of the live event.  The webinars will be available for unlimited on-demand viewing.  This virtual conference also offers increased reach for the global microbiology community with a high degree of interaction through live-streaming video and chat sessions.

Like the 2019 conference, this event will be produced on our robust platform, allowing you to watch, learn and connect seamlessly across all desktop or mobile devices. Equipped with gamification and point system, you can now move around the entire event, earning points for a chance to win one of LabRoots' most popular T-shirts.



Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2020 Immuno-Oncology Virtual Event. Submission is free. Submit your abstract here.

Continuing Education
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 30 credits.

Use #LRimmuno to follow the conversation!


Speakers
  • Diagnostics Segment Leader/Marketing Leader Cell Analysis, Cytiva
  • Professor, Pathology and Laboratory Medicine, Center for Immunology and Infectious Disease and UC Davis Comprehensive Cancer Center
  • PhD in Neuroimmunology from the University of Tübingen, Germany, Manager Immunology Screening Services at Horizon Discovery
  • Assistant Professor of Immunology, University of Pittsburgh, Hillman Cancer Center
  • Director, Precision Immunology Laboratory, Perlmutter Cancer Center, NYU Langone Health
  • Application Scientist - Advanced Cell Diagnostics
  • Technology Manager for Biosciences, GE Research Center
  • President, The Histochemical Society; Science Director for Cytiva
  • Professor Emeritus of Pathology, University of Arizona; Founder and Chief Scientific Advisor Emeritus, Ventana Medical Systems, Inc., a division of Roche
  • Director of the Melanoma Center and the Center for Immuno-Oncology, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School
  • Application Development Engineer
  • Senior Research Investigator II, Leads Discovery & Optimization, Bristol Myers Squibb, Princeton, NJ, USA
  • Postdoctoral Fellow, Laboratory of Dr. Philip Greenberg, Fred Hutchinson Cancer Research Center, Scholar of the Parker Institute for Cancer Immunotherapy
  • Assistant Research Physician, National Institutes of Health, National Cancer Institute, Genitourinary Malignancy Branch and the Laboratory of Tumor Immunology and Biology
  • Biomarkers & Cytometry Specialistm MilliporeSigma
  • Clinical Scientist, The Parker Institute for Cancer Immunotherapy, and Former Medical Oncology Fellow at the University of Texas MD Anderson Cancer Center
  • Assistant Professor | Department of Pediatrics, Division of Hematology/Oncology, University of Washington School of Medicine, Principal Investigator | Ben Towne Center for Childhood Cancer...
  • Senior Scientist, MilliporeSigma
  • Physician scientist at NCI (National Cancer Institute)
  • Chief Scientific Officer, Scribe Biosciences
  • Assistant Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
  • Product Manager of Neoantigen Peptide Services at GenScript

Show Resources
You May Also Like
JUL 29, 2020
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
JUL 29, 2020
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Immuno-Oncology & Cancer Biology The rapid development of immuno-oncology therapies has transformed the cancer treatment landscape. Discovering safe, potent, and persistent immune cell p...
NOV 12, 2020 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 12, 2020 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Ten years ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2020 Clinical Diagnostics and Research Virtual Event will again bring together clinicians,...
SEP 08, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
SEP 08, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is excited to bring academia and industry, research experts, virologists, microbiologists, healthcare professionals, and leading biomedical scientists under one roof at our 1st Annua...
OCT 07, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
OCT 07, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots and the Cancer Research and Oncology Planning Committee are pleased to announce the 8th Annual Cancer Research and Oncology Virtual Event! This 2-day event will take place on October...
APR 20, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
APR 20, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is excited to announce our 9th Annual Genetics Virtual Week held on April 20-22, 2021! Genetics Virtual Week 2021 will offer a multi-day content-rich program combining stellar exper...
MAY 05, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
MAY 05, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is pleased to announce our 3rd Forensic Sciences Virtual Event on May 5, 2021. Join us for this free, one-day event on May 5th as we discuss DNA, chemistry, toxicology, digital fore...
Agenda
  • Microfluidic precision autostainer for fast multiplexed TSA-based immunofluorescence
    JUN 03, 2020 4:00 PM PDT
    Microfluidic precision autostainer for fast multiplexed TSA-based immunofluorescence
    Alexandre Kehren, M.Sc.
    Application Development Engineer
    Sponsored By: Lunaphore
  • Spatial Mapping of Gene Expression in Tumors using the RNAscope™ Technology
    JUN 03, 2020 4:00 PM PDT
    Spatial Mapping of Gene Expression in Tumors using the RNAscope™ Technology
    Anushka Dikshit, PhD
    Application Scientist - Advanced Cell Diagnostics
    Sponsored By: Advanced Cell Diagnostics
  • The roles of neoantigen peptides in personalized medicine
    JUN 03, 2020 3:00 PM PDT
    The roles of neoantigen peptides in personalized medicine
    Samantha Zaroff, PhD
    Product Manager of Neoantigen Peptide Services at GenScript
    Sponsored By: GenScript
  • Dynamic Live Cell Imaging of Adherent and Immune Cells using CellASIC® ONIX2 Microfluidic Platform
    JUN 03, 2020 2:00 PM PDT
    Dynamic Live Cell Imaging of Adherent and Immune Cells using CellASIC® ONIX2 Microfluidic Platform
    Jun Park, PhD
    Senior Scientist, MilliporeSigma
    Sponsored By: MilliporeSigma
  • Gene manipulation in primary human immune cells: Successful strategies and applications for CRISPRko, RNAi and beyond
    JUN 03, 2020 1:00 PM PDT
    Gene manipulation in primary human immune cells: Successful strategies and applications for CRISPRko, RNAi and beyond
    Verena Brucklacher-Waldert, PhD
    PhD in Neuroimmunology from the University of Tübingen, Germany, Manager Immunology Screening Services at Horizon Discovery
    Sponsored By: Horizon Discovery
  • JUN 03, 2020 12:00 PM PDT
    How multiplexed imaging reveals key insights into the tumor microenvironment to inform treatment and improve outcomes
    Paul Goodwin
    President, The Histochemical Society; Science Direc...
    Fiona Ginty
    Technology Manager for Biosciences, GE Research Center
    Prachi Bogetto
    Diagnostics Segment Leader/Marketing Leader Cell Analys...
  • Single cell multiomic analysis of T-cell exhaustion
    JUN 03, 2020 12:00 PM PDT
    Single cell multiomic analysis of T-cell exhaustion
    Pratip K. Chattopadhyay, PhD
    Director, Precision Immunology Laboratory, Perlmutter Cancer Center, NYU Langone Health
    Sponsored By: BD
  • Keynote Presentation: Combinatorial Approaches to Immunotherapy: Melanoma as the Example
    JUN 03, 2020 11:00 AM PDT
    Keynote Presentation: Combinatorial Approaches to Immunotherapy: Melanoma as the Example
    Stephen Hodi, MD
    Director of the Melanoma Center and the Center for Immuno-Oncology, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School
  • Keynote Presentation: The Importance of Tissue Chemistry in Immunity-Oncology
    JUN 03, 2020 9:30 AM PDT
    Keynote Presentation: The Importance of Tissue Chemistry in Immunity-Oncology
    Thomas M. Grogan, MD
    Professor Emeritus of Pathology, University of Arizona; Founder and Chief Scientific Advisor Emeritus, Ventana Medical Systems, Inc., a division of Roche
    Sponsored By: Roche Diagnostics
  • Keynote Presentation: It is Time for TIME (Tumor Immune Microenvironment) in Experimental and Diagnostic Pathology
    JUN 03, 2020 8:00 AM PDT
    Keynote Presentation: It is Time for TIME (Tumor Immune Microenvironment) in Experimental and Diagnostic Pathology
    Alexander David Borowsky, MD
    Professor, Pathology and Laboratory Medicine, Center for Immunology and Infectious Disease and UC Davis Comprehensive Cancer Center
    Sponsored By: Leica Biosystems
  • JUN 03, 2020 7:00 AM PDT
    High throughput biomarker profiling for immuno-oncology research using MILLIPLEX® assays
    Sponsored By: MilliporeSigma
    Jenny Koenitzer, PhD
    Senior Research Investigator II, Leads Discovery & Opti...
    Yan Nikhamin, MS, MBA
    Biomarkers & Cytometry Specialistm MilliporeSigma
  • Keynote Presentation: Development of Rational Immunotherapy Combinations to Overcome the Immunosuppressive Prostate Tumor Microenvironment
    JUN 03, 2020 6:00 AM PDT
    Keynote Presentation: Development of Rational Immunotherapy Combinations to Overcome the Immunosuppressive Prostate Tumor Microenvironment
    Sumit K. Subudhi, MD, PhD
    Assistant Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
  • Checkpoint blockade-induced autoimmunity: Lessons from mouse models of type 1 diabetes
    Checkpoint blockade-induced autoimmunity: Lessons from mouse models of type 1 diabetes
    Tijana Martinov, PhD
    Postdoctoral Fellow, Laboratory of Dr. Philip Greenberg, Fred Hutchinson Cancer Research Center, Scholar of the Parker Institute for Cancer Immunotherapy
  • Clinical Development of Immunotherapy in Urothelial Cancer
    Clinical Development of Immunotherapy in Urothelial Cancer
    Scot Niglio, MD
    Assistant Research Physician, National Institutes of Health, National Cancer Institute, Genitourinary Malignancy Branch and the Laboratory of Tumor Immunology and Biology
  • Deciphering the function of B cells in human cancer
    Deciphering the function of B cells in human cancer
    Tullia C. Bruno, PhD
    Assistant Professor of Immunology, University of Pittsburgh, Hillman Cancer Center
  • Define challenges of tissue-based biomarker development for Immuno-Oncology Therapy
    Define challenges of tissue-based biomarker development for Immuno-Oncology Therapy
    Houssein Sater, MD
    Physician scientist at NCI (National Cancer Institute)
  • Microenvironment on Demand: A breakthrough technology for personalized cell therapy discoveries
    Microenvironment on Demand: A breakthrough technology for personalized cell therapy discoveries
    Maithreyan Srinivasan
    Chief Scientific Officer, Scribe Biosciences
  • Overcoming cell therapy barriers in the suppressive tumor microenvironment with engineered proteins
    Overcoming cell therapy barriers in the suppressive tumor microenvironment with engineered proteins
    Shannon K. Oda, PhD
    Assistant Professor | Department of Pediatrics, Division of Hematology/Oncology, University of Washington School of Medicine, Principal Investigator | Ben Towne Center for Childhood Cancer...
  • Primary and Acquired Resistance to Cancer Immunotherapy
    Primary and Acquired Resistance to Cancer Immunotherapy
    Leonardo Nissola, MD
    Clinical Scientist, The Parker Institute for Cancer Immunotherapy, and Former Medical Oncology Fellow at the University of Texas MD Anderson Cancer Center
  • Latest Trends in Immuno-Oncology
  • Microenvironment on Demand: A breakthrough technology for personalized cell therapy discoveries
    Microenvironment on Demand: A breakthrough technology for personalized cell therapy discoveries
    Maithreyan Srinivasan
    Chief Scientific Officer, Scribe Biosciences
  • Define challenges of tissue-based biomarker development for Immuno-Oncology Therapy
    Define challenges of tissue-based biomarker development for Immuno-Oncology Therapy
    Houssein Sater, MD
    Physician scientist at NCI (National Cancer Institute)
  • Overcoming cell therapy barriers in the suppressive tumor microenvironment with engineered proteins
    Overcoming cell therapy barriers in the suppressive tumor microenvironment with engineered proteins
    Shannon K. Oda, PhD
    Assistant Professor | Department of Pediatrics, Division of Hematology/Oncology, University of Washington School of Medicine, Principal Investigator | Ben Towne Center for Childhood Cancer...
  • Keynote Presentation: The Importance of Tissue Chemistry in Immunity-Oncology
    JUN 03, 2020 9:30 AM PDT
    Keynote Presentation: The Importance of Tissue Chemistry in Immunity-Oncology
    Thomas M. Grogan, MD
    Professor Emeritus of Pathology, University of Arizona; Founder and Chief Scientific Advisor Emeritus, Ventana Medical Systems, Inc., a division of Roche
    Sponsored By: Roche Diagnostics
  • JUN 03, 2020 12:00 PM PDT
    How multiplexed imaging reveals key insights into the tumor microenvironment to inform treatment and improve outcomes
    Paul Goodwin
    President, The Histochemical Society; Science Direc...
    Fiona Ginty
    Technology Manager for Biosciences, GE Research Center
    Prachi Bogetto
    Diagnostics Segment Leader/Marketing Leader Cell Analys...
  • Development and Clinical Applications of Cancer Immunotherapies
  • Clinical Development of Immunotherapy in Urothelial Cancer
    Clinical Development of Immunotherapy in Urothelial Cancer
    Scot Niglio, MD
    Assistant Research Physician, National Institutes of Health, National Cancer Institute, Genitourinary Malignancy Branch and the Laboratory of Tumor Immunology and Biology
  • Keynote Presentation: It is Time for TIME (Tumor Immune Microenvironment) in Experimental and Diagnostic Pathology
    JUN 03, 2020 8:00 AM PDT
    Keynote Presentation: It is Time for TIME (Tumor Immune Microenvironment) in Experimental and Diagnostic Pathology
    Alexander David Borowsky, MD
    Professor, Pathology and Laboratory Medicine, Center for Immunology and Infectious Disease and UC Davis Comprehensive Cancer Center
    Sponsored By: Leica Biosystems
  • Single cell multiomic analysis of T-cell exhaustion
    JUN 03, 2020 12:00 PM PDT
    Single cell multiomic analysis of T-cell exhaustion
    Pratip K. Chattopadhyay, PhD
    Director, Precision Immunology Laboratory, Perlmutter Cancer Center, NYU Langone Health
    Sponsored By: BD
  • Dynamic Live Cell Imaging of Adherent and Immune Cells using CellASIC® ONIX2 Microfluidic Platform
    JUN 03, 2020 2:00 PM PDT
    Dynamic Live Cell Imaging of Adherent and Immune Cells using CellASIC® ONIX2 Microfluidic Platform
    Jun Park, PhD
    Senior Scientist, MilliporeSigma
    Sponsored By: MilliporeSigma
  • Immunotherapeutic Modalities
  • Checkpoint blockade-induced autoimmunity: Lessons from mouse models of type 1 diabetes
    Checkpoint blockade-induced autoimmunity: Lessons from mouse models of type 1 diabetes
    Tijana Martinov, PhD
    Postdoctoral Fellow, Laboratory of Dr. Philip Greenberg, Fred Hutchinson Cancer Research Center, Scholar of the Parker Institute for Cancer Immunotherapy
  • Primary and Acquired Resistance to Cancer Immunotherapy
    Primary and Acquired Resistance to Cancer Immunotherapy
    Leonardo Nissola, MD
    Clinical Scientist, The Parker Institute for Cancer Immunotherapy, and Former Medical Oncology Fellow at the University of Texas MD Anderson Cancer Center
  • Deciphering the function of B cells in human cancer
    Deciphering the function of B cells in human cancer
    Tullia C. Bruno, PhD
    Assistant Professor of Immunology, University of Pittsburgh, Hillman Cancer Center
  • Keynote Presentation: Development of Rational Immunotherapy Combinations to Overcome the Immunosuppressive Prostate Tumor Microenvironment
    JUN 03, 2020 6:00 AM PDT
    Keynote Presentation: Development of Rational Immunotherapy Combinations to Overcome the Immunosuppressive Prostate Tumor Microenvironment
    Sumit K. Subudhi, MD, PhD
    Assistant Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
  • JUN 03, 2020 7:00 AM PDT
    High throughput biomarker profiling for immuno-oncology research using MILLIPLEX® assays
    Sponsored By: MilliporeSigma
    Jenny Koenitzer, PhD
    Senior Research Investigator II, Leads Discovery & Opti...
    Yan Nikhamin, MS, MBA
    Biomarkers & Cytometry Specialistm MilliporeSigma
  • Keynote Presentation: Combinatorial Approaches to Immunotherapy: Melanoma as the Example
    JUN 03, 2020 11:00 AM PDT
    Keynote Presentation: Combinatorial Approaches to Immunotherapy: Melanoma as the Example
    Stephen Hodi, MD
    Director of the Melanoma Center and the Center for Immuno-Oncology, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School
  • Gene manipulation in primary human immune cells: Successful strategies and applications for CRISPRko, RNAi and beyond
    JUN 03, 2020 1:00 PM PDT
    Gene manipulation in primary human immune cells: Successful strategies and applications for CRISPRko, RNAi and beyond
    Verena Brucklacher-Waldert, PhD
    PhD in Neuroimmunology from the University of Tübingen, Germany, Manager Immunology Screening Services at Horizon Discovery
    Sponsored By: Horizon Discovery
  • The roles of neoantigen peptides in personalized medicine
    JUN 03, 2020 3:00 PM PDT
    The roles of neoantigen peptides in personalized medicine
    Samantha Zaroff, PhD
    Product Manager of Neoantigen Peptide Services at GenScript
    Sponsored By: GenScript
  • Spatial Mapping of Gene Expression in Tumors using the RNAscope™ Technology
    JUN 03, 2020 4:00 PM PDT
    Spatial Mapping of Gene Expression in Tumors using the RNAscope™ Technology
    Anushka Dikshit, PhD
    Application Scientist - Advanced Cell Diagnostics
    Sponsored By: Advanced Cell Diagnostics
  • Microfluidic precision autostainer for fast multiplexed TSA-based immunofluorescence
    JUN 03, 2020 4:00 PM PDT
    Microfluidic precision autostainer for fast multiplexed TSA-based immunofluorescence
    Alexandre Kehren, M.Sc.
    Application Development Engineer
    Sponsored By: Lunaphore
Speakers

  • Prachi Bogetto
    Diagnostics Segment Leader/Marketing Leader Cell Analysis, Cytiva
    Biography
      Prachi Bogetto is responsible for product management and marketing within the Cellular Analysis business at Cytiva. She is a scientist by education, with degrees in biochemistry and molecular biology. Her career as a bench scientist was spent working on gene therapy when it was an idea only the most intrepid were investing in and she is thrilled to see some true patient benefit in recent years. She is especially optimistic about the promise of immunotherapies, including CAR-T therapies, to move cancer treatment forward.
    • Alexander David Borowsky, MD
      Professor, Pathology and Laboratory Medicine, Center for Immunology and Infectious Disease and UC Davis Comprehensive Cancer Center
      Biography
        Dr. Borowsky is a surgical and molecular pathologist with expertise in cancer diagnostics and model systems for cancer research. His research is primarily focused on human breast cancer and mouse models for this disease with extensive experience and accomplishments on many aspects of experimental pathology and animal models of human disease. He is a translational scientist with expertise in assay development and interpretation in the clinical setting, including experience with radiologic-pathologic image registration and comparative analysis, immunohistochemistry, FISH, and tissue and fixative preparation for conventional and innovative molecular analysis. His lab has pioneered techniques for mammary gland transplantation experiments, and has generated transgenic cancer models. Specific areas of interest in the laboratory include the tumor immune microenvironment, pre-cancer progression and cancer stem cell origins, cancer promoting microenvironments, and regulation of progression and reversion. The lab has a long track record of experimental pathology including interpretation of phenotypes, developmental and cancer, and interpretation of novel immunohistochemical studies, functional imaging technology, image analysis, and data informatics. Additional research interests extend to the development of novel in vivo imaging modalities, and use of these in preclinical and clinical trials. He directs clinical trials at UC Davis, including the completed Leica Genensis study for validation of digital whole slide imaging for pathology diagnosis, and ongoing WISDOM breast cancer screening, and the All of US NIH Precision medicine cohort studies; and leads the Pathology working group in the NCI MCL consortium and the PreCancer Atlas pilot project.
      • Verena Brucklacher-Waldert, PhD
        PhD in Neuroimmunology from the University of Tübingen, Germany, Manager Immunology Screening Services at Horizon Discovery
        Biography
          Verena is a Manager at Horizon Discovery Ltd, based in Cambridge, UK. Horizon Discovery is a world leader in the utilization of gene editing and gene modulation technologies to support the greater understanding of gene function, the genetic drivers behind human disease, and the development of molecular cell and gene therapies for precision medicine. The company's products and services are used by thousands of scientists working in academic institutes, pharmaceutical companies and clinical diagnostic laboratories around the globe. Verena received her doctorate in Neuroimmunology from the University of Tübingen, Germany, and gained a postdoctoral research fellowship from the German Research Foundation that enabled her to intensify her studies on T cell biology in Marc Veldhoen's lab in Cambridge, UK. Before Verena joined Horizon Discovery, she developed assays for hit identification and lead characterisation of multifunctional, oncology-relevant antibody-fragments for the biopharmaceutical company Crescendo Biologics. At Horizon Discovery she is managing a team of scientists, is providing high level scientific expertise and technical leadership for new and ongoing activities within the Immunology services team.
        • Tullia C. Bruno, PhD
          Assistant Professor of Immunology, University of Pittsburgh, Hillman Cancer Center
          Biography
            Tullia C. Bruno, PhD, is an Assistant Professor in the Department of Immunology at the University of Pittsburgh and a faculty member in the Tumor Microenvironment Center and the Cancer Immunology and Immunotherapy Program at the UPMC Hillman Cancer Center. She obtained her Ph.D. in Immunology from Johns Hopkins in 2010 and completed her postdoctoral fellowship at the University of Colorado in 2015-both with a focus in tumor immunology. While Dr. Bruno's PhD training focused on inhibitory receptors on intratumoral T cells, she became interested in the role of B cells in the tumor microenvironment (TME) during her postdoctoral fellowship and has built her independent research program around understanding intratumoral B cell function in multiple human cancers, in particular, lung and head and neck cancer. Dr. Bruno's research lab has an overt focus on studying immunity within cancer patients, which makes her research highly translational with the potential for future clinical trials targeting B cells. Thus, Dr. Bruno's overall research objective is to develop a B cell-specific immunotherapy in the next five to ten years.
          • Pratip K. Chattopadhyay, PhD
            Director, Precision Immunology Laboratory, Perlmutter Cancer Center, NYU Langone Health
            Biography
              Pratip Chattopadhyay, PhD is an Associate Professor (Pathology) and founding Director of NYU Langone Health's Precision Immunology Laboratory (PIL). His laboratory performs independent research in tumor immunology and provides cutting-edge immune monitoring services for a wide variety of biomedical disciplines (cancer, infectious disease, rheumatology). He uses high parameter cytometry technologies, including 30-parameter flow cytometry and combined protein/mRNA analysis by RNA sequencing (molecular cytometry), to reveal biomarkers that predict patient outcomes, better understand disease pathogenesis, and inform rational design of combination drug therapies. Dr. Chattopadhyay has a history of innovative work in the cytometry and immunoassay space. In 2005, as a post-doctoral fellow in Mario Roederer's laboratory (VRC/NIH), he developed a novel assay for enumeration and isolation of antigen-specific CD4+ T-cells, based on CD154 expression (Nature Medicine). In 2006, he reported the first 18-color flow cytometry experiments, which were used to comprehensively characterize antigen-specific T-cells against multiple antigenic epitopes in the same tube (Nature Medicine); this study was the first use of quantum dots for flow cytometry. This work increased the multiplexing capability of advanced flow cytometers, culminating in the development of an advanced 30-parameter flow cytometry system (co-led with the Roederer Lab and BD Biosciences). He also contributed to the development of CITE-seq (Nature Methods 2017). Finally, Dr. Chattopadhyay played a key role in the development of a number of bioinformatics tools for analyzing high parameter data, including SPICE (Roederer), FlowType and R-chyoptimyx (Aghaheepour and Brinkman), and CytoBrute, and a unique tool for building high parameter flow cytometry panels, known as Color Wheel. Dr. Chattopadhyay is a proud graduate of the Johns Hopkins Bloomberg School of Public Health (Ph.D.) and the University of Virginia (B.A.).
            • Anushka Dikshit, PhD
              Application Scientist - Advanced Cell Diagnostics
              Biography
                Anushka Dikshit, Ph.D. is an Application Scientist with Advanced Cell Diagnostics with background in cancer research and immuno-oncology. She is focused on expanding the applications of RNAscope technology for oncology research. Prior to working for ACD, Anushka was involved in identifying novel therapeutic targets for melanoma as a postdoctoral fellow at Duke University. She obtained her doctoral degree from Southern Illinois University, School of Medicine in Molecular Physiology.
              • Fiona Ginty
                Technology Manager for Biosciences, GE Research Center
                Biography
                  Fiona Ginty is a Technology Manager for Biosciences at General Electric's Research Center in Niskayuna, Upstate New York. For over a decade, she has led a multidisciplinary team that developed the Cell DIVE multiplexed immunofluorescence imaging technology. As part of their foundational research into multiplexing lab protocols, imaging hardware, and analysis software, the team collaborated with researchers across the US and globally to better understand their tissue imaging and biomarker needs. They then translated that back to Cell DIVE. To date, the team has published over 30 peer-reviewed articles on the technology and oncology applications. Prior to GE Research, Fiona was a senior scientist for the UK Medical Research Council, Cambridge UK and a post-doctoral scientist at Nestlé Research Center, Lausanne, Switzerland.
                • Paul Goodwin
                  President, The Histochemical Society; Science Director for Cytiva
                  Biography
                    Paul Goodwin is Science Director for Cytiva, formerly GE Healthcare Life Sciences, and resides in Seattle, WA. He studied biology at the University of California, San Diego and physiology and biophysics at the University of Washington, Seattle. He created and managed the Image Analysis Laboratory at the Fred Hutchinson Cancer Research Center in Seattle prior to joining Applied Precision, where he was effectively the Chief Scientific Officer (CSO) prior to its acquisition by GE Healthcare. He is the inventor of thirteen patents and has authored numerous peer-reviewed scientific papers and book chapters. He regularly teaches at the Marine Biological Laboratory in Woods Hole, MA, is the Co-Director of Immunohistochemistry and Microscopy at Montgomery College in Germantown, MD, and is the President of the Histochemical Society. He serves on a number of advisory councils and is a member of the Leadership Advisory Council for the Advanced Regenerative Manufacturing Institute.
                  • Thomas M. Grogan, MD
                    Professor Emeritus of Pathology, University of Arizona; Founder and Chief Scientific Advisor Emeritus, Ventana Medical Systems, Inc., a division of Roche
                    Biography
                      Dr. Thomas Grogan, MD, is professor emeritus at the University of Arizona College of Medicine. He is the founder and chief scientific advisor emeritus at Ventana Medical Systems, Inc., a division of Roche, a leading international healthcare leader based in Basel, Switzerland. Dr. Grogan grew up in unusual circumstances, as the son of a CIA officer father and a steel-willed mother, whose three sons experienced childhoods filled with peril in several foreign countries. He graduated from the University of Virginia, Phi Beta Kappa, with a degree in biology, and earned his medical degree with honors from the George Washington University School of Medicine. During his time in medical school, Dr. Grogan studied tropical medicine in Cebu, the Philippines. He did his internship and residency in the U.S. Army at Letterman Hospital in San Francisco and at Walter Reed Army Medical Center in Washington, D.C. He was a post-graduate fellow in hematopathology at Stanford University. A founding member of the International Lymphoma Study Group, Dr. Grogan has authored more than two hundred and fifty scientific papers and holds eighteen patents. His clinical practice contributions have been recognized in the Best Doctors in America, published by Woodward/White, Inc.) continuously from 1991 until his retirement in 2017. Chief among his innovations is the automation of cancer pathology testing technology that enables physicians to accurately identify the genetic characteristics of their patients' disease and manage their personalized treatment. Dr. Grogan has also been recognized for his medical and business accomplishments with many prestigious awards, including American Cancer Society Gift of Life Award (2003), Ernst and Young Entrepreneur of the Year Award (2002), Tom Brown Excellence in Entrepreneurship Award (2002), University of Arizona Outstanding Technology Innovation Award (2004). Dr. Grogan is a husband, father and grandfather, and he lives in Tucson, Arizona, with his wife of fifty-two years, Cande, who was a successful restaurateur.
                    • Stephen Hodi, MD
                      Director of the Melanoma Center and the Center for Immuno-Oncology, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School
                      Biography
                        Dr. F. Stephen Hodi is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women's Cancer Center, the Sharon Crowley Martin Chair in Melanoma at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. Dr. Hodi is a graduate of Harvard University and Cornell University Medical College. He completed his postdoctoral training in In¬ternal Medicine at the Hospital of the University of Pennsylvania and his medical oncology training at Dana-Farber cancer Institute, where he joined the faculty in 1998. His research focuses on gene therapy, the development of immune therapies, and first into human studies for malignant melanoma. Dr. Hodi is a member of the National Comprehensive Cancer Network, the American Society of Clinical Oncology, the American Association for Cancer Research, the Eastern Cooperative Oncology Group Melanoma Committee, the Society for Immunotherapy of Cancer, the European Academy of Tumor Immunology and a founding member of the Society for Melanoma Research. Dr. Hodi is an internationally recognized leader in the development of immune therapy and melanoma therapeutics. In particular, he is known for the clinical development of immune checkpoint inhibitors. His clinical investigation efforts have pioneered the use of immune checkpoint blockade and combinatorial approaches to treat cancer. His publications include articles in the Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and the New England Journal of Medicine.
                      • Alexandre Kehren, M.Sc.
                        Application Development Engineer
                        Biography
                          Alexandre Kehren graduated in Engineering with a specialization in Biomechanics at the Polytechnic School of Paris and later obtained his M.Sc. degree in Bioengineering at the EPFL in 2018. After a 1-year lab immersion in a microsystems laboratory at EPFL, he joined Lunaphore to complete his master thesis on the development of multiplexed fluorescent immunoassays for tumor micro-environment analysis. He is now part of Lunaphore's R&D team as Application Development Engineer, in charge of the development and optimization of protocols for multiplexing applications.
                        • Jenny Koenitzer, PhD
                          Senior Research Investigator II, Leads Discovery & Optimization, Bristol Myers Squibb, Princeton, NJ, USA
                          Biography
                            Dr. Koenitzer is an immunobiologist in R&D at Bristol Myers Squibb in Princeton, NJ. During her time at BMS, she has focused on small molecule and biologics drug discovery in the immuno-oncology space.
                          • Tijana Martinov, PhD
                            Postdoctoral Fellow, Laboratory of Dr. Philip Greenberg, Fred Hutchinson Cancer Research Center, Scholar of the Parker Institute for Cancer Immunotherapy
                            Biography
                              Dr. Tijana Martinov is a postdoctoral research fellow in the laboratory of Dr. Philip Greenberg at the Fred Hutchinson Cancer Research Center, and a Scholar of the Parker Institute for Cancer Immunotherapy. She earned her Ph.D. at the University of Minnesota, where she investigated how immune checkpoint blockade, used to treat many types of cancer, impacts self-reactive T and B cells. Her thesis work in the laboratory of Dr. Brian Fife resulted in several first author publications and awards, and sparked Tijana's interest in designing safe and effective cancer immunotherapies.
                            • Scot Niglio, MD
                              Assistant Research Physician, National Institutes of Health, National Cancer Institute, Genitourinary Malignancy Branch and the Laboratory of Tumor Immunology and Biology
                              Biography
                                Dr. Scot Niglio graduated from Villanova University with a Bachelor of Science in biology where he was inducted into the Phi Beta Kappa Honor Society and went on to receive a Master of Science in physiology from Georgetown University. He then earned a Master of Science in clinical and translational science at the University of Medicine and Dentistry of New Jersey (now Rutgers University) in combination with his medical degree. He completed his internal medicine residency as well as a hematology and medical oncology fellowship at the Icahn School of Medicine at Mount Sinai. Dr. Niglio has received honors such as the Young Investigator Award (2019) from the Conquer Cancer Foundation (ASCO) and he has been named "40 under 40 in Cancer" (2019) by the Lynx Group. This award recognizes the contributions being made by rising stars and emerging leaders across the field of cancer research under the age of 40. Dr. Niglio is on faculty at the National Institutes of Health as an Assistant Research Physician with a joint appointment in the Genitourinary Malignancy Branch and the Laboratory of Tumor Immunology and Biology. His research focuses on developing treatments for genitourinary cancers.
                              • Yan Nikhamin, MS, MBA
                                Biomarkers & Cytometry Specialistm MilliporeSigma
                                Biography
                                  Yan Nikhamin is an immunoassay specialist at MilliporeSigma, based in New York. He is trained in Cell and Molecular Biology and has worked in developing CAR-T cells. Yan has been with MilliporeSigma for 9 years helping our customers by sharing his experience.
                                • Leonardo Nissola, MD
                                  Clinical Scientist, The Parker Institute for Cancer Immunotherapy, and Former Medical Oncology Fellow at the University of Texas MD Anderson Cancer Center
                                  Biography
                                    Leo Nissola is a Medical Doctor, Scientist, and Published Book Author in Immunology. He is a former Medical Oncology Fellow at the University of Texas MD Anderson Cancer Center in Houston. His work focuses on Clinical Development, accelerating research, and exploring novel approaches to tackle cancer with immunotherapy at The Parker Institute For Cancer Immunotherapy.
                                  • Shannon K. Oda, PhD
                                    Assistant Professor | Department of Pediatrics, Division of Hematology/Oncology, University of Washington School of Medicine, Principal Investigator | Ben Towne Center for Childhood Cancer...
                                    Biography
                                      Dr. Shannon Oda earned a Ph.D. in Immunology from the University of Colorado Anschutz Medical Campus and completed her postdoctoral training with Dr. Philip Greenberg at the Fred Hutchinson Cancer Research Center. She has received several awards, including the Evergreen Fund Award and the LLS Career Development Program Special Fellow Award, and has been invited to give talks internationally. Dr. Oda joined the Seattle Children's Research Institute in 2020, where she is an Assistant Professor at the Ben Towne Center for Childhood Cancer Research and the University of Washington School of Medicine. Her research focuses on improving T cell immunotherapy, which uses immune cells to target and destroy cancer cells. She has identified several obstacles that inhibit immune cells from effectively eradicating tumor and she is inventing new ways to engineer T cells to overcome these obstacles and improve immunotherapy of hematological and solid tumors.
                                    • Jun Park, PhD
                                      Senior Scientist, MilliporeSigma
                                      Biography
                                        Jun Park, Ph. D. is Senior Scientist and Applications Lead at MilliporeSigma. He studied Biomaterials and Immunology at University of Toronto and did his postdoctoral work at Harvard Medical School investigating small molecule regulators of beta integrins. Since joining MilliporeSigma in 2006, his primary works have focused on the novel detection technologies, Western blotting, and cell based assays.
                                      • Houssein Sater, MD
                                        Physician scientist at NCI (National Cancer Institute)
                                        Biography
                                          Dr. Sater is a translational physician scientist (hematologist/oncologist) with special interest in immune therapy of cancer. He leads the Genitourinary Malignancies Branch efforts at understanding the role of cancer immunotherapy on the tumor (immune and non-immune) micro-environment. Dr Sater is one of the few nationally recognized experts in tissue-based multiplex biomarker development and multispectral imaging. The Society of Immune Therapy of Cancer (SITC) chose him as one of 29 young leader investigators to tackle one of the major hurdles in immune therapy in a funded consortium effort (Sparkathon Timios Project). He also has an interest in demographics (gender, race, age, BMI) effect on immune therapy as a biomarker for better personalized medicine.
                                        • Maithreyan Srinivasan
                                          Chief Scientific Officer, Scribe Biosciences
                                          Biography
                                            After post-doctoral work at Johns Hopkins University Medical School, Dr. Srinivasan started out as an entry-level scientist in CuraGen and conceived a process to normalize and sequence expressed sequence tags for multiple tissues. The database of sequence tags was then used in conjunction with an in-house differential gene expression technology to identify novel, therapeutically-relevant proteins/targets, at least one of which is in advanced clinical trials (Glembatumumab vedotin, Celldex Therapeutics). Starting 2000 to 2008, Dr. Srinivasan held various positions to launch the first next generation DNA-sequencer, Roche/454 GS20. Two generations of sequencers later, Dr. Srinivasan co-lead the effort to sequence the first human genome using next generation DNA sequencing. Starting 2008, Dr. Srinivasan was head of Global Genomics R and D at Agilent Technologies where he oversaw the launch of 70+ products/product extensions. Dr. Srinivasan joined WaferGen as Chief Technology Officer where he conceived the idea to repurpose WaferGen's SmartChip technology to perform single-cell genomics and lead the development of both the ICELL8 system as well as the alpha prototype of the SMARTer ICELL8-CX system. WaferGen was subsequently acquired by Takara Bio USA in March 2017. Dr. Srinivasan currently is Chief Scientific Officer at Scribe Biosciences. Dr. Srinivasan graduated with a Ph.D. from Colorado State University.
                                          • Sumit K. Subudhi, MD, PhD
                                            Assistant Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
                                            Biography
                                              Dr. Sumit Subudhi is a medical oncologist and immunologist whose research focuses on the mechanisms and pathways within the immune system that are responsible for tumor rejection and clinical benefit. Dr. Subudhi's medical training began when he enrolled in the MD/PhD program at The University of Chicago Pritzker School of Medicine in 1998. Dr. Subudhi's predoctoral studies included examining the role of B7-H1 (PD-L1), an immune checkpoint, in regulating T cell-mediated immune responses. He completed his PhD in 2004, his MD in 2007, his internal medicine residency at the New York-Presbyterian Hospital/Weill Cornell Medical Center in 2009, and his medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) in 2013. During his medical training, Dr. Subudhi became interested in the field of tumor immunology and subsequently worked in Dr. James P. Allison's laboratory at MSKCC during his fellowship years. In Dr. Allison's laboratory, Dr. Subudhi began to examine the effects of targeting immune checkpoints (e.g., CTLA-4 and PD-1) in prostate cancer and continues to uncover the mechanisms that tumors use to evade the immune system. After completing his fellowship at MSKCC, Dr. Subudhi was appointed as an Advanced Scholar Instructor at MD Anderson Cancer Center in 2013, and as an Assistant Professor in the department of Genitourinary Medical Oncology in 2014. His emphasis is on developing optimal immune checkpoint therapy-based combinations and identifying immunological biomarkers to predict treatment responses, with the hope of ultimately producing durable and even curative responses in patients with prostate cancer. Dr. Subudhi was awarded the Prostate Cancer Foundation (PCF) Young Investigator Award in 2014 and the V Foundation Award (Lloyd Family Clinical Oncology Scholar) in 2017 to pursue these studies. More recently, Dr. Subudhi has been investigating the immunological differences within the primary and metastatic prostate tumor microenvironments. In addition, he has been focused on identifying predictive biomarkers for immune-related adverse events (irAEs) to minimize toxicities and maximize benefit to immune checkpoint therapies.
                                            • Samantha Zaroff, PhD
                                              Product Manager of Neoantigen Peptide Services at GenScript
                                              Biography
                                                Samantha Zaroff Ph.D. is the product manager of Neoantigen peptide services at GenScript. Prior to this position, Dr. Zaroff received her Ph.D. in Molecular Biology from Rowan University focusing on translational research on neurodegenerative disorders. Dr. Zaroff has worked at GenScript for three years after receiving her Ph.D. as product manager for a range of immunology based services such as reagent antibody generation, antibody drug discovery, and reagent peptide services.
                                              Posters

                                              POSTER SUBMISSION GUIDELINES

                                              Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.


                                              SUBMIT YOUR ABSTRACT

                                              Enter the following information to this Submission Form:

                                              • Poster Title
                                              • Your Name
                                              • Your Institution
                                              • Your Email
                                              • Abstract describing the poster


                                              All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

                                              If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

                                              Questions? Email Posters@LabRoots.com

                                              LabRoots Policy

                                              Sponsored by

                                              For information on becoming a sponsor or exhibitor, please click here.


                                              C.E. Credits

                                              The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                                              Help

                                              General LabRoots Questions

                                              email support@labroots.com  

                                              Virtual Events and Webinars

                                              Supported Configurations

                                              • Operating System Internet Explorer Firefox Chrome Safari
                                                Vista IE8+ FF10+ Chrome15+
                                                Windows 7 IE8+ FF10+ Chrome15+
                                                Windows 8 IE10 FF10+ Chrome15+
                                                Mac OS X   FF10+ Chrome15+ Safari5.1+
                                              • Cookie settings: session cookies enabled
                                              • Browser configuration must have JavaScript enabled
                                              • Adobe Flash player 10.2 or later

                                              To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                              Internet Connection

                                              • A minimum of 100Kbps is recommended for audio-only events
                                              • A minimum of 300Kbps is recommended for speaker on-video events

                                              Computer Equipment

                                              • Screen Resolution: Minimum 1024x768
                                              • Video Card: 65,000 colors minimum
                                              • Sound card and speakers (or headphones) for hearing webcast in full format
                                              • Audio Card: 16-bit minimum
                                              • RAM: 512MB of free RAM

                                              Firewall Protocol

                                              • HTTP on port 80 or HTTPS on port 443
                                              • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                              • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                              Work-At-Home Attendees

                                              • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                              For A Seamless Experience

                                              When using a mobile device, FREE Mobile Apps are available:

                                              - For viewing Webinars:

                                              - For viewing Virtual Events

                                              Attendee Guide

                                              • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                              Virtual Event and Webinar Support:

                                              Continuing Education (CME/CE) Support

                                              Loading Comments...
                                              Show Resources
                                              Attendees
                                              • See more